| Dr John G Southard, MD | |
|
1 Edmundson Pl, Suite 312, Council Bluffs, IA 51503-4658 | |
| (712) 396-4295 | |
| (712) 396-4298 |
| Full Name | Dr John G Southard |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 46 Years |
| Location | 1 Edmundson Pl, Council Bluffs, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104967090 | NPI | - | NPPES |
| 1133413 | Medicaid | IA | |
| 47244 | Other | IA | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 22453 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Jennie Edmundson | Council bluffs, IA | Hospital |
| Myrtue Medical Center | Harlan, IA | Hospital |
| Chi Health Mercy Council Bluffs | Council bluffs, IA | Hospital |
| Entity Name | Pulmonary Infectious Disease Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083755821 PECOS PAC ID: 5193617264 Enrollment ID: O20040325000936 |
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration approval for its biosimilar filgrastim product, Nivestim.
Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the U.S. and Europe, a drug that resolves tophi in less than one year would become the patient share leader in the chronic tophaceous gout patient subpopulation and would be used in the vast majority of patients who suffer severe tophaceous gout, according to surveyed U.S. and European rheumatologists.
Osteoporosis, a condition characterized by weak and fragile bones, develops when there is an imbalance in the remodeling process and more bone is lost than replaced. Now, new research published by Cell Press in the November issue of the journal Cell Stem Cell uncovers a mechanism that may guide development of better strategies for treatment osteoporosis.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John G Southard, MD 1 Edmundson Pl, Suite 312, Council Bluffs, IA 51503-4658 Ph: (712) 396-4295 | Dr John G Southard, MD 1 Edmundson Pl, Suite 312, Council Bluffs, IA 51503-4658 Ph: (712) 396-4295 |
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration approval for its biosimilar filgrastim product, Nivestim.
Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the U.S. and Europe, a drug that resolves tophi in less than one year would become the patient share leader in the chronic tophaceous gout patient subpopulation and would be used in the vast majority of patients who suffer severe tophaceous gout, according to surveyed U.S. and European rheumatologists.
Osteoporosis, a condition characterized by weak and fragile bones, develops when there is an imbalance in the remodeling process and more bone is lost than replaced. Now, new research published by Cell Press in the November issue of the journal Cell Stem Cell uncovers a mechanism that may guide development of better strategies for treatment osteoporosis.
› Verified 4 days ago
Anand Deshmukh, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Edmundson Pl, Ste. #306, Council Bluffs, IA 51503 Phone: 712-396-7787 Fax: 712-396-4115 | |
John W Marshall, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 201 Ridge St, Suite 202, Council Bluffs, IA 51503 Phone: 712-325-0022 Fax: 712-325-8102 | |
Dr. Erica K. Cichowski, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1702 N 16th St, Council Bluffs, IA 51501 Phone: 712-256-7223 Fax: 712-256-7669 | |
Dr. Vikrant Salaria, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Mercy Dr, Suite 120, Council Bluffs, IA 51503 Phone: 712-388-2770 Fax: 712-388-2771 | |
Dr. Kevin Crowley, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Edmundson Pl, Suite 310, Council Bluffs, IA 51503 Phone: 712-396-4300 Fax: 712-396-7069 | |
Christopher J Holewinski, RP, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Mercy Dr, Council Bluffs, IA 51503 Phone: 712-328-5490 Fax: 712-325-2499 | |
Dr. Kalpana Kumar Puri, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 201 Ridge St Ste 312, Council Bluffs, IA 51503 Phone: 712-322-5532 Fax: 712-309-0193 |